Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG 3350 for Nerve Repair
NCT03236064Phase 1Terminated
- Sponsor
- WellSpan Health
- Start
- May 2016
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 1 trial of polyethylene glycol 3350 in nerve injury, sponsored by WellSpan Health. Primary endpoint: Return of function at 12 months. Started May 2016; status: terminated.
02
Drugs
polyethylene glycol 3350
03
Conditions
nerve injury
Beyond the preview
Go deeper on NCT03236064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236064.